Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Products & comparisons
Product source

DSLD label record: FINAFLEX Creatine Fruit Punch powder

This DSLD record lists FINAFLEX Creatine Fruit Punch as a powder with creatine monohydrate at 5 grams per labelled serving. It is a label declaration only, not evidence of efficacy, safety or approval. [1]

Automatic summary · not editorially reviewed

Label · NIH DSLD
Creatine Fruit PunchOriginal label · NIH DSLD
Creatine Fruit Punch

FROM THE ORIGINAL LABEL

A closer look at the product

Pack contents
11 Ounce(s) · 313 Gram(s)
Label serving
6.3–12.6 Gram(s)
Servings per container
50
Barcode / SKU
8 10020 72307 6
Open original label (PDF)
Ingredients & declared amounts1

Amounts from the label, per specified serving. These are manufacturer declarations, not a personal dosage recommendation.

IngredientAmountPer label serving
Creatine Monohydrate5 Gram(s)6.3 Gram(s)

Other ingredients: Citric Acid, Natural and Artificial Fruit Punch Flavor, Malic Acid, Sucralose, Silica

Source: National Institutes of Health, Office of Dietary Supplements · Dietary Supplement Label Database. Label snapshot; packaging and formulation may have changed.

The key findings

  1. DSLD record 334085 lists FINAFLEX Creatine Fruit Punch as a powder in the Non-Nutrient/Non-Botanical category. [1]

  2. The label declares creatine monohydrate at 5 grams per labelled serving. [1]

  3. DSLD inclusion does not establish efficacy, safety, FDA approval, laboratory verification or current retail availability. [1]

The source at a glance

Brand
FINAFLEX
Form
Powder
Pack contents
11 Ounce(s) · 313 Gram(s)
Label serving
6.3–12.6 Gram(s)
Ingredients listed
Creatine Monohydrate
Record type / format
Dietary supplement label/database record
Scope / context
The described product: FINAFLEX Creatine Fruit Punch powder, not a patient population.
Summary based on
Product label / database record

FINAFLEX powder record in the NIH DSLD

The source is record 334085 in the NIH Office of Dietary Supplements Dietary Supplement Label Database. The declared product name is Creatine Fruit Punch and the declared brand is FINAFLEX. The physical form on the label is powder, and the DSLD product category is Non-Nutrient/Non-Botanical. The label entered the database on 2025-09-25; the source notes this is not a product launch date.

Supporting source [1]

Declared ingredient: creatine monohydrate 5 grams

The only declared ingredient with an amount in this record is creatine monohydrate, listed at 5 grams per labelled serving. This is a label fact, not personal dosing advice. The record supplies no independent product testing, price or batch certificate.

Supporting source [1]

What DSLD inclusion does not establish

The source states that DSLD inclusion does not establish efficacy, safety, FDA approval, laboratory verification or current retail availability. The snapshot describes label declarations only. It is not a study, an independent lab test or an endorsement.

Supporting source [1]

How to interpret this

Product label record; not evidence of efficacy or approval. The snapshot covers label declarations only; no independent testing, price, batch certificate or retail availability is supplied.

Based on a product label or database record. This does not establish effectiveness, independent batch testing, approval or current availability.

Source & supporting passages

[1]
Creatine Fruit Punch

FINAFLEX · dsld.od.nih.gov

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    Physical form on label: Powder
  2. Finding 2 ↑

    Creatine Monohydrate: 5 Gram(s) per labelled serving
  3. Finding 3 ↑

    DSLD inclusion does not establish efficacy, safety,

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…